| – | Overall Cohort | Apixaban Cohort | Dabigatran Cohort | Rivaroxaban Cohort | Warfarin Cohort | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | N | % | |
| Overall Study Population | 468 | 100.0% | 147 | 31.4% | 98 | 20.9% | 156 | 33.3% | 67 | 14.3% |
| Baseline Comorbidities/Procedures | - | - | - | - | - | - | - | - | - | - |
| Diabetes Mellitus | 182 | 38.9% | 60 | 40.8% | 34 | 34.7% | 55 | 35.3% | 33 | 49.3% |
| Hypertension | 350 | 74.8% | 119 | 81.0% | 75 | 76.5% | 104 | 66.7% | 52 | 77.6% |
| Ischemic Stroke | 26 | 5.6% | 10 | 6.8% | 7 | 7.1% | 4 | 2.6% | 5 | 7.5% |
| Hemorrhagic Stroke | 2 | 0.4% | - | 0.0% | - | 0.0% | 1 | 0.6% | 1 | 1.5% |
| Bleeding (Gastrointestinal, Intracranial, Other) | 65 | 13.9% | 19 | 12.9% | 12 | 12.2% | 13 | 8.3% | 21 | 31.3% |
| Systemic Embolism | 5 | 1.1% | 2 | 1.4% | 1 | 1.0% | 2 | 1.3% | - | 0.0% |
| Cardioversion | 16 | 3.4% | 3 | 2.0% | 3 | 3.1% | 8 | 5.1% | 2 | 3.0% |
| Peripheral Artery Disease | 8 | 1.7% | 1 | 0.7% | 2 | 2.0% | 2 | 1.3% | 3 | 4.5% |
| Anemia | 55 | 11.8% | 17 | 11.6% | 7 | 7.1% | 12 | 7.7% | 19 | 28.4% |
| Congestive Heart Failure | 70 | 15.0% | 35 | 23.8% | 11 | 11.2% | 11 | 7.1% | 13 | 19.4% |
| Renal Disease | 45 | 9.6% | 13 | 8.8% | 6 | 6.1% | 8 | 5.1% | 18 | 26.9% |
| Myocardial Infarction | 16 | 3.4% | 7 | 4.8% | - | 0.0% | 5 | 3.2% | 4 | 6.0% |
| Peripheral Vascular Disease | 131 | 28.0% | 35 | 23.8% | 25 | 25.5% | 43 | 27.6% | 28 | 41.8% |
| Transient Ischemic Attack | 9 | 1.9% | 2 | 1.4% | 1 | 1.0% | 4 | 2.6% | 2 | 3.0% |
| Coronary Artery Disease | 153 | 32.7% | 44 | 29.9% | 31 | 31.6% | 48 | 30.8% | 30 | 44.8% |